DUBLIN – A re-evaluation of psychedelic drugs as potential therapies for major depressive disorder, anxiety, post-traumatic stress disorder and other neuropsychiatric conditions has been underway for some time, but this broad effort gained further momentum during 2020, as commercial firms started to raise money at the level needed to enable the field to start moving from small-scale academic studies to the kind of industry-scale trials that will be needed to convince regulators, patients and physicians that these molecules could become viable treatment options.